Premium
Chemotherapy Programs of the National Prostatic Cancer Project (NPCP)
Author(s) -
SCHMIDT JOSEPH D.,
SCOTT WILLIAM W.,
GIBBONS ROBERT,
JOHNSON DOUGLAS E.,
PROUT GEORGE R.,
LOENING STEFAN,
SOLOWAY, MARK,
DEKERNION JEAN,
PONTES J. EDSON,
SLACK NELSON H.,
MURPHY GERALD P.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.1980.45.s7.1937
Subject(s) - medicine , cyclophosphamide , chemotherapy , oncology , clinical trial , vincristine , estramustine , cancer , surgery , prostate cancer , prostate disease
Results of the first nationally randomized trial of the National Prostatic Cancer Project revealed a demonstrable advantage for chemotherapy in the management of advanced disease (Stage D in relapse from endocrine therapy). Both cyclophosphamide and 5‐Fluorouracil showed improved activity over standard therapy. A second trial for patients previously irradiated, with less tolerance to myelosuppressive agents, revealed an advantage for estramustine phosphate and streptozotocin over standard therapy. Subsequently completed trials have revealed activity for prednimustine and imidazole carboxamide (DTIC). Trials currently underway for newly‐diagnosed Stage D and for Stage D disease clinically stable to diethylstilbestrol (DES) show promising activity for DES combined with cyclophosphamide. Current trials with single agents in advanced disease are comparing methyl‐CCNU and hydroxyurea with cyclophosphamide; another is evaluating estramustine phosphate and vincristine alone and in combination. The use of chemotherapy in earlier staged patients as adjuvants to definitive surgery or irradiation is underway in two clinical trials, where the effect of cyclophosphamide and estramustine phosphate as long‐term therapies is compared with no additional treatment.